Caring Ambassadors Hepatitis C Program Newsletter
www.HepCChallenge.org
May 2010
Clinical
Trials, Cohort Studies, Pilot Studies
Telaprevir for previously treated
chronic HCV infection. McHutchison JG, Manns MP, Muir AJ, et al. N Engl J
Med. 2010 Apr 8;362(14):1292-303.
http://www.ncbi.nlm.nih.gov/pubmed/20375406
Peginterferon alpha-2a Plus
Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic
Outcomes and Tolerability From the LATINO Study. Balart
LA, Lisker-Melman M, Hamzeh FM, et al. Am J Gastroenterol. 2010 Apr 13. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20389293
Effectiveness of hepatitis C
treatment with pegylated interferon and ribavirin in urban minority patients. Feuerstadt
P, Bunim AL, Garcia H, et al. Hepatology. 2010 Apr;51(4):1137-43.
Distribution of different
hepatitis C virus genotypes in patients with hepatitis C virus infection. Bokharaei
Salim F, Keyvani H, Amiri A, et al. World J Gastroenterol. 2010 Apr
28;16(16):2005-9.
http://www.ncbi.nlm.nih.gov/pubmed/20419838
Twelve weeks posttreatment
follow-up is as relevant as 24 weeks to determine the sustained virologic
response in patients with hepatitis C virus receiving pegylated interferon and
ribavirin. Martinot-Peignoux M, Stern C, Maylin S, et al. Hepatology.
2010 Apr;51(4):1122-6.
http://www.ncbi.nlm.nih.gov/pubmed/20069649
Extrahepatic manifestations
associated with chronic hepatitis C infections in Poland.
Zarebska-Michaluk
DA, Lebensztejn DM, Kryczka WM, Skiba E. Adv Med Sci. 2010 Apr 6:1-7. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20371429
Hepatocellular carcinoma in
individuals with HBV infection or HBV-HCV co-infection in a low endemic
country. Davíđsdóttir L, Duberg AS, Törner A, et al. Scand J
Gastroenterol. 2010 Apr 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20384529
Hormone therapy in Brazilian
postmenopausal women with chronic hepatitis C: a pilot study. Padua
MA, Fonseca AM, Deguti MM, et al. Climacteric. 2010 Apr;13(2):179-86.
http://www.ncbi.nlm.nih.gov/pubmed/19657792
Plasma
prohepcidin levels in patients with chronic viral hepatitis: relationship with
liver fibrosis. Olmez
OF, Gurel S, Yilmaz Y. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):461-5.
http://www.ncbi.nlm.nih.gov/pubmed/19940783
Disease progression from chronic
hepatitis C to cirrhosis and hepatocellular carcinoma is associated with
repression of interferon regulatory factor-1. Zekri
AR, Moharram RA, Mohamed WS, et al. Eur J Gastroenterol Hepatol. 2010
Apr;22(4):450-6.
http://www.ncbi.nlm.nih.gov/pubmed/19858727
Complication rate of percutaneous
liver biopsies among persons with advanced chronic liver disease in the HALT-C
Trial. Seeff LB, Everson GT, Morgan TR, et al. Clin Gastro-enterol
Hepatol. 2010 Apr 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20362695
High rates of sustained
virological response in hepatitis C virus-infected injection drug users
receiving directly observed therapy with peginterferon alpha-2a (40KD)
(PEGASYS) and once-daily ribavirin. Waizmann M, Ackermann G. J Subst Abuse Treat. 2010
Jun;38(4):338-45. Epub 2010 Apr 1.
http://www.ncbi.nlm.nih.gov/pubmed/20362408
Low vitamin D serum level is
related to severe fibrosis and low responsiveness to interferon-based therapy
in genotype 1 chronic hepatitis C. Petta S, Cammŕ C, Scazzone C, et al. Hepatology.
2010 Apr;51(4):1158-67.
http://www.ncbi.nlm.nih.gov/pubmed/20162613
Hepatobiliary
function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of
fibrosis in chronic hepatitis: histopathological correlation. Kula M, Karacavus S, Baskol M, et
al. Nucl Med Commun. 2010 Apr;31(4):280-5.
http://www.ncbi.nlm.nih.gov/pubmed/20087241
Outcome
of a hepatitis C outbreak among patients in a pain management clinic. Fazili J, Mallonee S, Tierney WM,
et al. Dig Dis Sci. 2010 Apr 22. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20411419
Basic
and Applied Science, Pre-Clinical Studies
Soluble angiogenesis factors in
sera of Egyptian patients with hepatitis C virus infection: correlation with
disease severity. Talaat RM. Viral Immunol. 2010 Apr;23(2):151-7.
http://www.ncbi.nlm.nih.gov/pubmed/20373995
Natural
epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte
activity.
Wang S, Buchli R, Schiller J, et
al. World J Gastroenterol. 2010 Apr 28;16(16):1953-69.
http://www.ncbi.nlm.nih.gov/pubmed/20419832
Consistent
beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1
human leukocyte antigen-C following exposure to hepatitis C virus. Knapp S, Warshow U, Hegazy D, et
al. Hepatology. 2010 Apr;51(4):1168-75.
http://www.ncbi.nlm.nih.gov/pubmed/20077564
Cyclic
sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease
inhibitors: synthesis and evaluation of inhibitors with improved potency and
pharmacokinetic profiles. Velázquez
F, Sannigrahi M, Bennett F, et al. J Med Chem. 2010 Apr 22;53(8):3075-85.
http://www.ncbi.nlm.nih.gov/pubmed/20302300
The
protease domain increases the translocation stepping efficiency of the
hepatitis C virus NS3-4A helicase. Rajagopal
V, Gurjar M, Levin MK, Patel SS. J Biol Chem. 2010 Apr 2. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20363755
A
small molecule inhibits HCV replication and alters NS4B's subcellular
distribution.
Bryson PD, Cho NJ, Einav S, et
al. Antiviral Res. 2010 Apr 2. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20363257
Cleavage
of mitochondrial antiviral signaling protein in the liver of patients with
chronic hepatitis C correlates with a reduced activation of the endogenous
interferon system.
Bellecave P, Sarasin-Filipowicz
M, et al. Hepatology. 2010 Apr;51(4):1127-36.
http://www.ncbi.nlm.nih.gov/pubmed/20044805
Core-specific
adaptive regulatory T-cells in different outcomes of hepatitis C. Langhans B, Braunschweiger I,
Arndt S, et al. Clin Sci (Lond). 2010 Apr 20;119(2):97-109.
http://www.ncbi.nlm.nih.gov/pubmed/20222873
Amino
acid substitutions in the hepatitis C virus core region of genotype 1b affect
very early viral dynamics during treatment with telaprevir, peginterferon, and
ribavirin. Akuta
N, Suzuki F, Hirakawa M, et al. J Med Virol. 2010 Apr;82(4):575-82.
http://www.ncbi.nlm.nih.gov/pubmed/20166188
CXC
chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver
fibrosis. Zaldivar
MM, Pauels K, von Hundelshausen P, et al.
http://www.ncbi.nlm.nih.gov/pubmed/20162727
Positive
selection of core 70Q variant genotype 1b hepatitis c virus strains induced by
pegylated interferon and ribavirin. Kurbanov
F, Tanaka Y, Matsuura K, et al. J Infect Dis. 2010 Apr 26. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20420509
HIV/HCV
Coinfection
Clearance of hepatitis C virus
RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from
peripheral blood mononuclear cells. Page EE, Cox A, Atkins M, Nelson MR. AIDS. 2010 Apr
9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20386424
Hepatitis C virus RNA detection
in different semen fractions of HCV/HIV-1 co-infected men by nested PCR. Savasi
V, Parrilla B, Ratti M, Oneta M, Clerici M, Ferrazzi E. Eur J Obstet Gynecol
Reprod Biol. 2010 Apr 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20382466
Ability of treatment week 12
viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV
coinfected patients. Van den Eynde E, Tiraboschi JM, Tural C, et al. AIDS.
2010 Apr 24;24(7):975-82.
http://www.ncbi.nlm.nih.gov/pubmed/20299963
Hepatitis C infection on immune
recovery in HIV-positive patients on successful HAART: the role of genotype 3. Seminari
E, Tinelli C, Ravasi G, et al. Curr HIV Res. 2010 Apr 1;8(3):186-93.
http://www.ncbi.nlm.nih.gov/pubmed/20163342
Is statin therapy safe in
patients with HIV/hepatitis C coinfection? Stroup JS, Harris B. Proc
(Bayl Univ Med Cent). 2010 Apr;23(2):111-3.
http://www.ncbi.nlm.nih.gov/pubmed/20396416
Complementary
and Alternative Medicine
A novel approach to evaluate
traditional Chinese medicine treatment outcomes using pattern identification. Berle
CA, Cobbin D, Smith N, Zaslawski C. J Altern Complement Med. 2010
Apr;16(4):357-67.
http://www.ncbi.nlm.nih.gov/pubmed/20374102
Aminofeel improves the
sensitivity to taste in patients with HCV-infected liver disease.
Nagao
Y, Matsuoka H, Kawaguchi T, Sata M. Med Sci Monit. 2010 Apr 1;16(4):PI7-12.
http://www.ncbi.nlm.nih.gov/pubmed/20357731
Epidemiology,
Diagnostics, and Miscellaneous Works
Treatment of HBV/HCV coinfection.
Potthoff A, Manns MP, Wedemeyer H. Expert Opin Pharmacother. 2010
Apr;11(6):919-28.
http://www.ncbi.nlm.nih.gov/pubmed/20166841
Prevalence
of hepatitis B and hepatitis C virus infections in France in 2004: social
factors are important predictors after adjusting for known risk factors. Meffre C, Le Strat Y,
Delarocque-Astagneau E, et al. J Med Virol. 2010 Apr;82(4):546-55.
http://www.ncbi.nlm.nih.gov/pubmed/20166185
Analysis
of hepatitis C virus strains circulating in Republic of the Congo. Cantaloube JF, Gallian P, Bokilo
A, et al. J Med Virol. 2010 Apr;82(4):562-7.
http://www.ncbi.nlm.nih.gov/pubmed/20166180
Hepatitis
C virus infection in a Japanese leprosy sanatorium for the past 67 years.
Shiogama K, Teramoto H, Morita Y,
et al. J Med Virol. 2010 Apr;82(4):556-61.
http://www.ncbi.nlm.nih.gov/pubmed/20166169
Performance
evaluation of the Abbott RealTime HCV Genotype II for hepatitis C virus
genotyping. Sohn
YH, Ko SY, Kim MH, Oh HB. Clin Chem Lab Med. 2010 Apr;48(4):469-74.
http://www.ncbi.nlm.nih.gov/pubmed/20128734
Identification
of substance use and dependence among patients with viral hepatitis.
Jackson CB, Varon J, Ho A, et al.
Dig Liver Dis. 2010 Apr 23. [Epub ahead of print]
Marks KM, Talal AH, Kreek MJ.
http://www.ncbi.nlm.nih.gov/pubmed/20418192
Comorbidities
associated with the increasing burden of hepatitis C infection. Basseri B, Yamini D, Chee G,
Enayati PD, Tran T, Poordad F. Liver Int. 2010 Apr 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20408945
Excellent
superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic
change during pegylated interferon alpha-2b plus ribavirin treatment. Ogawa E, Furusyo N, Toyoda K, et
al. BMC Gastroenterol. 2010 Apr 16;10(1):38. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20398383
Poor
sleep quality predicts onset of either major depression or subsyndromal
depression with irritability during interferon-alpha treatment. Franzen PL, Buysse DJ, Rabinovitz
M, Pollock BG, Lotrich FE. Psychiatry Res. 2010 May 15;177(1-2):240-245. Epub
2010 Apr 9.
http://www.ncbi.nlm.nih.gov/pubmed/20381876
Serum apoptotic caspase activity
in chronic hepatitis C and nonalcoholic Fatty liver disease. Papatheodoridis
GV, Hadziyannis E, Tsochatzis E, et al. J Clin Gastroenterol. 2010
Apr;44(4):e87-95.
http://www.ncbi.nlm.nih.gov/pubmed/19881359
Evaluation of a rapid,
point-of-care test device for the diagnosis of hepatitis C infection.
Lee SR,
Yearwood GD, Guillon GB, et al. Clin Virol. 2010 May;48(1):15-7. Epub 2010 Apr
1.
http://www.ncbi.nlm.nih.gov/pubmed/20362493
Noninvasive markers of fibrosis
and inflammation in clinical practice: prospective comparison with liver
biopsy. Anastasiou J, Alisa A, Virtue S, et al. Eur J
Gastroenterol Hepatol. 2010 Apr;22(4):474-80.
http://www.ncbi.nlm.nih.gov/pubmed/19887952